A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on Aleniglipron Pharmacokinetics
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Summary
The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.
Eligibility
- Age range
- 18–85 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening. 2. BMI ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg 3. Understands the study procedures in the ICF and is willing and able to comply with the protocol and communicate effectively with study personnel. 4. Group 1 only: Participant has severe RI maintained on stable regimen of high-flux HD at least 3 times per week for at least 3 months 5. Group 2 only: Has normal renal function with eGFR ≥ 90 mL/min Exclusion Criteria: 1. History or presence of alcohol or drug abuse within the pas…
Interventions
- DrugAleniglipron
Administered orally
Location
- Research SiteOrlando, Florida